Biohybrid neural interfaces: an old idea enabling a completely new space of possibilities
Open full post
PRIMA Clinical Trial Data Safety Monitoring Board Votes to Recommend PRIMA Device for Submission for European Approval
Science Announces Positive Preliminary Results For Vision Restoration In Pivotal Clinical Trial
Science Corp Announces New Suite of Neural Engineering Products to Accelerate Innovation and Reduce Complexity & Cost Industry Wide
SciFi: Ruggedized, WiFi-Enabled Synapse-Compatible Headstage
Synapse: Flexible, Powerful Standard API for Neural Interface Devices
Prioritizing the Science Eye and PRIMA
Science Corporation Welcomes Tricia Gugler as Chief Financial Officer, Alex Feerst as Chief Legal Officer, and Joe Mornin as General Counsel
Brain-Computer Interfaces and Patients' Rights: Some Key Principles
Durham County Commissioners Unanimously Approve Incentives for Science Foundry Expansion
Nixels and Pixels: Introducing Science's Chip Families for Neural Recording And Stimulation
Press Kit
Science in the news
-
"Implant made with living neurons connects to mouse brains"
—New Scientist, December 4, 2024
-
"The Age of Neural Engineering (ft. Science Corp.)"
—S3, November 23, 2024
-
Science Corporation aims "to help blind people see"
—Bloomberg, November 13, 2024
-
Science Corporation's "retinal implant allowed some people who lost their central vision to read, play cards, and recognize faces"
—Wired, October 25, 2024
-
Science's "Brain Computer Toolkit"
—Bloomberg, October 17, 2024
-
"Bionic Eye Gets a New Lease of Life"
—IEEE Spectrum, May 21, 2024
-
"Restoring sight is possible now with optogenetics"
—The Washington Post, April 23, 2024
About Science
Science Corporation develops brain-computer interface (BCI) technology and conducts research on how neural engineering can restore quality of life to patients with debilitating conditions for which there are no treatment options. We are working on creating medical devices aimed at restoring vision, cognition, and mobility, and have dozens of patients in six countries enrolled in our clinical trials.
Learn moreContact
For press inquiries, please contact press@science.xyz.
